Engaging transgender clients in exploring sexuality – including intersectionality with gender identity and shifts in attraction associated with medical affirmation—is integral to the larger, clinical goal of affirming transgender identities and providing competent care. In this webinar, Dr. Alex Keuroghlian, MD MPH, will review recent research as well as existing best behavioral health practices and therapeutic considerations for sexual health among transgender clients, including the following topics: sexual identities and fluidity, sexual satisfaction following medical affirmation, and relational health. Attention is given to providing a transgender-affirming frame and discussing sexual health risk within the context of psychosocial stressors, including challenges related to gender affirmation and experiences of transphobia.
Learning Resources — HIV/STI Treatment and Prevention
In this talk Dr. Asa Radix will help participants understand how the HIV epidemic affects transgender people by examining the barriers to care for those newly diagnosed, specific strategies for medication adherence, and gender-affirmation strategies to improve health care experiences.
This module provides a deeper dive into pre-exposure prophylaxis (PrEP) for HIV prevention through clinical cases. The module contains three cases, each describing a different scenario where PrEP may be an option for the patient. The module also includes video interactions between providers and patients to help model conversations around PrEP.
The CDC reports that 83% of primary and secondary syphilis cases occur among gay, bisexual, and other men who have sex with men (MSM). With syphilis on the rise, health centers have an opportunity to prevent, screen, and treat syphilis among these vulnerable populations. In this webinar, Kevin Ard, MD, MPH will explain the diagnostic and therapeutic approach to syphilis based on the clinical stage of the disease, and will explain what to do when there are discordant results on diagnostic tests. Dr. Ard will be joined by Brenda Hernandez, who will explain syphilis case reporting and partner services so that health centers can effectively work with public health departments to help control the epidemic.
- Filed under
- HIV/STI Treatment and Prevention
The HIV epidemic disproportionately affects the Southern U.S., where 51% of new HIV diagnoses occurred in 2013. Despite substantial progress along the continuum of care, HIV remains a major health concern in the South, particularly for young, Black gay and bisexual men, other men who have sex men (MSM), and transgender women. Our new publication “HIV Prevention in the South: Reducing Stigma, Increasing Access” presents four strategic elements for preventing the further spread of HIV among vulnerable populations in the South, and suggests a more hopeful future for reducing the HIV epidemic.
Transgender Women and Pre-exposure Prophylaxis for HIV Prevention: What We Know and What We Still Need to Know
The National Center for Innovation in HIV Care
Transgender women are at elevated risk of becoming infected with HIV. Pre-exposure prophylaxis for HIV prevention (PrEP) is effective in reducing the risk of HIV infection among men who have sex with men (MSM), heterosexual men and women, and people who inject drugs (PWID). While transgender women have been included in some clinical trials of PrEP, no study has shown PrEP to be effective in reducing transgender women’s HIV risk.
The Food & Drug Administration (FDA) recently approved the use of an HIV treatment medication for HIV-negative people at high risk of getting HIV through sexual exposure. Known as “pre-exposure prophylaxis”—or PrEP—this medication is a once-a-day pill to be used in combination with condoms and other safer sex behavioral strategies to reduce risk. Protecting Yourself from HIV through PrEP informs consumers about PrEP and how it works, as well as other ways they can work with their health care providers to protect themselves against HIV.
Approximately 3.2 million individuals in the United States are infected with chronic hepatitis C (HCV) infection. While injection drug use is the most common mode of transmission, growing evidence indicates that the virus is also being spread through sexual contact, particularly among HIV-infected men who have sex with men (MSM). In this clinical brief, we review what is known about the epidemiology of HCV among HIV-infected MSM, as well as current screening, treatment, and prevention recommendations for HCV.
- Filed under
- HIV/STI Treatment and Prevention
This module provides an overview of HIV incidence and prevalence in the United States, highlights groups most at risk for contracting HIV, describes the current state of HIV and STI screening, and explains biomedical and other interventions effective to curb the transmission of HIV. Using a case study, participants will be guided through effective screening and prevention methods, as well as communication strategies for talking to patients about their care.
Human papilloma virus (HPV), one of the most common sexually transmitted infections, is preventable through a vaccine now recommended for all females and males age 11 to 26. However, vaccination rates remain low in the U.S., in part because only one-third of doctors prescribe the vaccine to eligible patients. HPV infection can lead to genital warts and certain types of cancer. This brief provides an analysis of the current state of HPV vaccination rates in the U.S., finding them lagging well behind other countries, where vaccination campaigns have been more successful.
The brief also describes barriers to vaccine uptake, and examines insurance coverage of HPV vaccine, including what vaccine guidelines mean for insurance coverage under the Affordable Care Act. The brief concludes with policy recommendations, including encouraging or mandating HPV vaccination through social institutions such as the military and publicly-funded universities; increasing vaccine delivery by providers and at STI clinics; reducing vaccine costs; and researching why there are gaps in HPV vaccine awareness and rates.